Intractable membranous lupus nephritis showing selective improvement of subepithelial deposits with tacrolimus therapy: a case report

2013 ◽  
Vol 80 (08) ◽  
pp. 140-145 ◽  
Author(s):  
Kanae Nonaka ◽  
Yoshifumi Ubara ◽  
Tatsuya Suwabe ◽  
Kenmei Takaichi ◽  
Kenichi Oohashi
Keyword(s):  
Case Report ◽  
Lupus Nephritis ◽  
Tacrolimus Therapy ◽  
Membranous Lupus Nephritis

Case report: successful treatment of membranous lupus nephritis with belimumab in an African female immigrant

2015 ◽  
Vol 35 (6) ◽  
pp. 1649-1653 ◽  
Author(s):  
Marie-Angélique De Scheerder ◽  
O. Boey ◽  
E. Mahieu ◽  
J. Vanuytsel ◽  
Anne-Marie Bogaert
Keyword(s):  
Case Report ◽  
Lupus Nephritis ◽  
Successful Treatment ◽  
Female Immigrant ◽  
Membranous Lupus Nephritis

scholarly journals CYCLOPHOSPHAMIDE FOR LUPUS NEPHRITIS CAUSING PRES (REVERSIBLE POSTERIOR ENCEPHALOPATHY SYNDROME): CASE REPORT

2019 ◽  
Author(s):  
ANDRÉ ADALBERTO PETRY ◽  
DEBORAH COLOMBO ◽  
MARIANA ANDRADE ◽  
JULIANA DELFINO ◽  
THIAGO ALBERTO FERNANDES GOMES DOS SANTOS ◽  
...  
Keyword(s):  
Case Report ◽  
Lupus Nephritis ◽  
Posterior Encephalopathy ◽  
Reversible Posterior Encephalopathy Syndrome

scholarly journals In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes

2021 ◽  
pp. ASN.2020081181 ◽  
Author(s):  
Aishwarya Ravindran ◽  
Marta Casal Moura ◽  
Fernando C. Fervenza ◽  
Samih H. Nasr ◽  
Mariam P. Alexander ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Kidney Biopsy ◽  
Interstitial Fibrosis ◽  
Study Cohort ◽  
Lower Serum ◽  
Tubular Atrophy ◽  
Novel Proteins ◽  
Biopsy Specimens ◽  
Membranous Lupus Nephritis

BackgroundIn patients with secondary (autoimmune) membranous nephropathy, two novel proteins, Exostosin 1 and Exostosin 2 (EXT1/EXT2), are potential disease antigens, biomarkers, or both. In this study, we validate the EXT1/EXT2 findings in a large cohort of membranous lupus nephritis.MethodsWe conducted a retrospective cohort study of patients with membranous lupus nephritis, and performed immunohistochemistry studies on the kidney biopsy specimens against EXT1 and EXT2. Clinicopathologic features and outcomes of EXT1/EXT2-positive versus EXT1/EXT2-negative patients were compared.ResultsOur study cohort included 374 biopsy-proven membranous lupus nephritis cases, of which 122 (32.6%) were EXT1/EXT2-positive and 252 (67.4%) were EXT1/EXT2-negative. EXT1/EXT2-positive patients were significantly younger (P=0.01), had significantly lower serum creatinine levels (P=0.02), were significantly more likely to present with proteinuria ≥3.5 g/24 h (P=0.009), and had significantly less chronicity features (glomerulosclerosis, P=0.001 or interstitial fibrosis and tubular atrophy, P<0.001) on kidney biopsy. Clinical follow-up data were available for 160 patients, of which 64 (40%) biopsy results were EXT1/EXT2-positive and 96 (60%) were EXT1/EXT2-negative. The proportion of patients with class 3/4 lupus nephritis coexisting with membranous lupus nephritis was not different between the EXT1/EXT2-positive and EXT1/EXT2-negative groups (25.0% versus 32.3%; P=0.32). The patients who were EXT1/EXT2-negative evolved to ESKD faster and more frequently compared with EXT1/EXT2-positive patients (18.8% versus 3.1%; P=0.003).ConclusionsThe prevalence of EXT1/EXT2 positivity was 32.6% in our cohort of membranous lupus nephritis. Compared with EXT1/EXT2-negative membranous lupus nephritis, EXT1/EXT2-positive disease appears to represent a subgroup with favorable kidney biopsy findings with respect to chronicity indices. Cases of membranous lupus nephritis that are EXT1/EXT2-negative are more likely to progress to ESKD compared with those that are EXT1/EXT2-positive.

scholarly journals Tacrolimus-induced bilateral optic neuropathy: A case report

2021 ◽  
pp. 4-4
Author(s):  
Lepsa Zoric ◽  
Aleksandra Ilic ◽  
Emina Colak ◽  
Milos Mirkovic ◽  
Jelica Pantelic ◽  
...  
Keyword(s):  
Case Report ◽  
Adverse Effects ◽  
Optic Neuropathy ◽  
Vision Loss ◽  
White Male ◽  
Immunosuppressive Drug ◽  
Organ Rejection ◽  
Toxic Optic Neuropathy ◽  
Tacrolimus Therapy ◽  
Male Patients

Intrduction. Tacrolimus (fujimycin or FK506) is a potent immunosuppressive drug with growing usage. It is usually used in prevention of transplanted organ rejection. Its use is highly valuable, but like other immunosupressants, it has adverse effects. One of them is optic neuropathy. Case report. A 47-year-old white male patients who had received tacrolimus therapy for nine years, after kidney transplantation, developed a subacute, painless vision loss on both eyes. He was thoroughly examined on different possible optic neuropathies and other causes of vision loss. After exclusion of other possible causes, the diagnosis of toxic optic neuropathy was established. His therapy was converted to cyclosporine, by his nephrologist, but his vision had improved only slightly. Conclusion. Toxic optic neuropathies are presented in everyday ophthalmological practice, but they are underestimated. Diagnosis can be demanding, especially when it comes to drugs and substances whose possible toxic effect on the optic nerve is not widely known. Unlike other adverse effects of tacrolimus therapy on nervous system, optic neuropathy can causes great and permanent functional impairment.

Sign in / Sign up

Export Citation Format

Share Document